Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Cancer genomics: promises and complexities.

W Zhang¹, P M Labordé, K R Coombes

¹Cancer Genomics and Proteomics Program, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|August 8, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.

NPJ precision oncology·2022

Same author

Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same author

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Same author

A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia.

Nature biomedical engineering·2019

Same author

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).

Breast cancer research and treatment·2016

Genomic biology is revolutionizing cancer research by enabling a deeper understanding of complex diseases and the development of personalized therapies. This genomic approach offers new avenues for identifying cancer targets and improving disease classification.

Area of Science:

Genomics
Cancer Research
Molecular Biology

Background:

The complete human genome is nearing deciphering.
High-throughput technologies are advancing rapidly.
Cancer research is transitioning from molecular to genomic biology.

Purpose of the Study:

To review developments in genomic technologies for cancer research.
To discuss challenges and future trends in genomic cancer research.
To highlight the potential of genomic approaches in understanding and treating cancer.

Main Methods:

Review of current genomic technologies and their applications in cancer.
Analysis of target identification and disease classification advancements.
Discussion of potential challenges and future directions.

Related Experiment Videos

Main Results:

Genomic technologies are yielding significant results in cancer target identification.
Genomic approaches are enhancing cancer disease classification.
The field shows promise for developing patient-tailored cancer therapies.

Conclusions:

Genomic biology represents a paradigm shift in cancer research.
Further refinement of genomic tools is necessary.
Genomic approaches hold immense potential for future cancer understanding and treatment.